MEDICLINIC INTERNATIONAL PLC

Director's Dealing • Apr 27, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4649M

Mediclinic International plc

27 April 2018

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

27 April 2018

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 8 and 10 January 2018, the Waledro Trust, a testamentary trust of which Dr Edwin Hertzog, chairman of the Board of directors of Mediclinic, is the sole trustee, transferred its entire holdings in the Company to the beneficiaries of the trust at the cost price. Dr Hertzog is not a beneficiary of the trust.

The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Waledro Trust

2.

Reason for the notification

a)

Position / status

The Waledro Trust is a testamentary trust of which Dr Edwin Hertzog, chairman of the Board of directors of the Company, is the sole trustee. Dr Hertzog is not a beneficiary of the trust.

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Transfer of shares to beneficiaries of trust at the cost price.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
ZAR 200.08 per share	13,281

d)

Aggregated information

Aggregated volume

Price

13,281

ZAR 200.08

e)

Date of the transaction

8 January 2018

f)

Place of the transaction

Johannesburg Stock Exchange

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Transfer of shares to beneficiaries of trust at the cost price.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
ZAR 200.08 per share	2

d)

Aggregated information

Aggregated volume

Price

2

ZAR 200.08

e)

Date of the transaction

10 January 2018

f)

Place of the transaction

Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with current operating divisions in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 33 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 hospitals and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 27 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com  

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom  

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBLGDSXBDBGIR